Evotec SE released a company presentation outlining its strategy for mid-term value creation across four levers: above-market growth with improved earnings quality, operational excellence through cost-out and productivity measures, increased monetization of Just Evotec Biologics technology and assets, and potential milestone and royalty returns from its asset pipeline. The presentation also describes market trends supporting outsourcing in drug discovery and biologics manufacturing, and provides details on the planned sale of the Just Evotec Biologics EU Toulouse J.POD site to Sandoz, including an upfront payment of about US$350 million, additional transition-period revenues of more than US$300 million for 2026–2028, and royalties linked to a portfolio of biosimilars. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.